Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 30;9(1):00615-2022.
doi: 10.1183/23120541.00615-2022. eCollection 2023 Jan.

Triple therapy in COPD: understanding the data

Samy Suissa  1   2
Affiliations
Editorial

Triple therapy in COPD: understanding the data

Samy Suissa. ERJ Open Res. .

Abstract

Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW.

PubMed Disclaimer

Conflict of interest statement

Provenance: Submitted article, peer reviewed. Conflict of interest: The author attended scientific advisory committee meetings or received speaking fees from AstraZeneca, Atara, Boehringer Ingelheim, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer and Seqirus.

Figures

FIGURE 1
FIGURE 1
Hazard ratio (HR) of a moderate or severe COPD exacerbation comparing single-inhaler triple therapy with single-inhaler dual bronchodilators in patients with COPD in the first year after treatment initiation, among patients with no prior inhaled corticosteroids (ICS), comparing results from the Informing the Pathway of COPD Treatment (IMPACT) and Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) randomised trials, and from the observational real-world study. The HR was not reported in the IMPACT trial and thus was estimated from the reported rate ratio.
FIGURE 2
FIGURE 2
Hazard ratio (HR) of all-cause mortality comparing single-inhaler triple therapy with single-inhaler dual bronchodilators in patients with COPD in the first year after treatment initiation, among patients with no prior inhaled corticosteroids (ICS), comparing results from the Informing the Pathway of COPD Treatment (IMPACT) and Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) randomised trials, and from the observational real-world study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Singh D, Agusti A, Anzueto A, et al. . Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J 2019; 53: 1900164. doi:10.1183/13993003.00164-2019 - DOI - PubMed
    1. Lipson DA, Barnhart F, Brealey N, et al. . Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671–1680. doi:10.1056/NEJMoa1713901 - DOI - PubMed
    1. Papi A, Vestbo J, Fabbri L, et al. . Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076–1084. doi:10.1016/S0140-6736(18)30206-X - DOI - PubMed
    1. Rabe KF, Martinez FJ, Ferguson GT, et al. . Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383: 35–48. doi:10.1056/NEJMoa1916046 - DOI - PubMed
    1. Lipson DA, Crim C, Criner GJ, et al. . Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 201: 1508–1516. doi:10.1164/rccm.201911-2207OC - DOI - PMC - PubMed

Publication types

LinkOut - more resources